Even prior to trial onset, researchers could use AI for non-invasive, radiographic tumor phenotyping in order to assess susceptibility to treatment (e.g., evaluating PD-L1 status for patients prior to a trial for anti-PD-L1 monoclonal antibodies) and select patients most likely to achieve clinical benefit. Here, CD274 is linked to neoplasm.